Cargando…
Imatinib Mesylate for the Treatment of Canine Mast Cell Tumors: Assessment of the Response and Adverse Events in Comparison with the Conventional Therapy with Vinblastine and Prednisone
Mast cell tumors (MCTs) are common neoplasms in dogs, and treatments for these diseases include surgery, polychemotherapy and targeted therapy with tyrosine kinase inhibitors. This study aimed to evaluate the response and the adverse events of treatment with imatinib mesylate (IM) compared to conven...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8834544/ https://www.ncbi.nlm.nih.gov/pubmed/35159380 http://dx.doi.org/10.3390/cells11030571 |
_version_ | 1784649213376724992 |
---|---|
author | Macedo, Thais Rodrigues de Queiroz, Genilson Fernandes Casagrande, Thaís Andrade Costa Alexandre, Pâmela Almeida Brandão, Paulo Eduardo Fukumasu, Heidge Melo, Samanta Rios Dagli, Maria Lucia Zaidan Pinto, Ana Carolina B. C. Fonseca Matera, Julia Maria |
author_facet | Macedo, Thais Rodrigues de Queiroz, Genilson Fernandes Casagrande, Thaís Andrade Costa Alexandre, Pâmela Almeida Brandão, Paulo Eduardo Fukumasu, Heidge Melo, Samanta Rios Dagli, Maria Lucia Zaidan Pinto, Ana Carolina B. C. Fonseca Matera, Julia Maria |
author_sort | Macedo, Thais Rodrigues |
collection | PubMed |
description | Mast cell tumors (MCTs) are common neoplasms in dogs, and treatments for these diseases include surgery, polychemotherapy and targeted therapy with tyrosine kinase inhibitors. This study aimed to evaluate the response and the adverse events of treatment with imatinib mesylate (IM) compared to conventional therapy using vinblastine and prednisolone (VP) in canine cutaneous MCTs. Twenty-four dogs were included in the study; 13 animals were treated with IM and 11 with VP. Tumor tissue samples were submitted for histological diagnosis, grading and KIT immunostaining. The response to treatment was assessed by tomographic measurements according to VCOG criteria. Adverse events were classified according to VCOG-CTCAE criteria. The IM and VP groups had dogs with similar breeds, gender, ages, MCT localization, WHO stages and lymph node metastasis profiles. Most MCTs were grade 2/low and had KIT- patterns 2 and 3. The objective response rate (ORR) was significantly higher (30.79%) in the IM group then in VP group (9.09%). Adverse events (AE) in IM group were all grade 1, significantly different from VP. In conclusion, IM presented better ORR and less severe adverse events when compared to VP, representing a suitable option for the treatment of low-grade canine MCTs. |
format | Online Article Text |
id | pubmed-8834544 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-88345442022-02-12 Imatinib Mesylate for the Treatment of Canine Mast Cell Tumors: Assessment of the Response and Adverse Events in Comparison with the Conventional Therapy with Vinblastine and Prednisone Macedo, Thais Rodrigues de Queiroz, Genilson Fernandes Casagrande, Thaís Andrade Costa Alexandre, Pâmela Almeida Brandão, Paulo Eduardo Fukumasu, Heidge Melo, Samanta Rios Dagli, Maria Lucia Zaidan Pinto, Ana Carolina B. C. Fonseca Matera, Julia Maria Cells Article Mast cell tumors (MCTs) are common neoplasms in dogs, and treatments for these diseases include surgery, polychemotherapy and targeted therapy with tyrosine kinase inhibitors. This study aimed to evaluate the response and the adverse events of treatment with imatinib mesylate (IM) compared to conventional therapy using vinblastine and prednisolone (VP) in canine cutaneous MCTs. Twenty-four dogs were included in the study; 13 animals were treated with IM and 11 with VP. Tumor tissue samples were submitted for histological diagnosis, grading and KIT immunostaining. The response to treatment was assessed by tomographic measurements according to VCOG criteria. Adverse events were classified according to VCOG-CTCAE criteria. The IM and VP groups had dogs with similar breeds, gender, ages, MCT localization, WHO stages and lymph node metastasis profiles. Most MCTs were grade 2/low and had KIT- patterns 2 and 3. The objective response rate (ORR) was significantly higher (30.79%) in the IM group then in VP group (9.09%). Adverse events (AE) in IM group were all grade 1, significantly different from VP. In conclusion, IM presented better ORR and less severe adverse events when compared to VP, representing a suitable option for the treatment of low-grade canine MCTs. MDPI 2022-02-07 /pmc/articles/PMC8834544/ /pubmed/35159380 http://dx.doi.org/10.3390/cells11030571 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Macedo, Thais Rodrigues de Queiroz, Genilson Fernandes Casagrande, Thaís Andrade Costa Alexandre, Pâmela Almeida Brandão, Paulo Eduardo Fukumasu, Heidge Melo, Samanta Rios Dagli, Maria Lucia Zaidan Pinto, Ana Carolina B. C. Fonseca Matera, Julia Maria Imatinib Mesylate for the Treatment of Canine Mast Cell Tumors: Assessment of the Response and Adverse Events in Comparison with the Conventional Therapy with Vinblastine and Prednisone |
title | Imatinib Mesylate for the Treatment of Canine Mast Cell Tumors: Assessment of the Response and Adverse Events in Comparison with the Conventional Therapy with Vinblastine and Prednisone |
title_full | Imatinib Mesylate for the Treatment of Canine Mast Cell Tumors: Assessment of the Response and Adverse Events in Comparison with the Conventional Therapy with Vinblastine and Prednisone |
title_fullStr | Imatinib Mesylate for the Treatment of Canine Mast Cell Tumors: Assessment of the Response and Adverse Events in Comparison with the Conventional Therapy with Vinblastine and Prednisone |
title_full_unstemmed | Imatinib Mesylate for the Treatment of Canine Mast Cell Tumors: Assessment of the Response and Adverse Events in Comparison with the Conventional Therapy with Vinblastine and Prednisone |
title_short | Imatinib Mesylate for the Treatment of Canine Mast Cell Tumors: Assessment of the Response and Adverse Events in Comparison with the Conventional Therapy with Vinblastine and Prednisone |
title_sort | imatinib mesylate for the treatment of canine mast cell tumors: assessment of the response and adverse events in comparison with the conventional therapy with vinblastine and prednisone |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8834544/ https://www.ncbi.nlm.nih.gov/pubmed/35159380 http://dx.doi.org/10.3390/cells11030571 |
work_keys_str_mv | AT macedothaisrodrigues imatinibmesylateforthetreatmentofcaninemastcelltumorsassessmentoftheresponseandadverseeventsincomparisonwiththeconventionaltherapywithvinblastineandprednisone AT dequeirozgenilsonfernandes imatinibmesylateforthetreatmentofcaninemastcelltumorsassessmentoftheresponseandadverseeventsincomparisonwiththeconventionaltherapywithvinblastineandprednisone AT casagrandethaisandradecosta imatinibmesylateforthetreatmentofcaninemastcelltumorsassessmentoftheresponseandadverseeventsincomparisonwiththeconventionaltherapywithvinblastineandprednisone AT alexandrepamelaalmeida imatinibmesylateforthetreatmentofcaninemastcelltumorsassessmentoftheresponseandadverseeventsincomparisonwiththeconventionaltherapywithvinblastineandprednisone AT brandaopauloeduardo imatinibmesylateforthetreatmentofcaninemastcelltumorsassessmentoftheresponseandadverseeventsincomparisonwiththeconventionaltherapywithvinblastineandprednisone AT fukumasuheidge imatinibmesylateforthetreatmentofcaninemastcelltumorsassessmentoftheresponseandadverseeventsincomparisonwiththeconventionaltherapywithvinblastineandprednisone AT melosamantarios imatinibmesylateforthetreatmentofcaninemastcelltumorsassessmentoftheresponseandadverseeventsincomparisonwiththeconventionaltherapywithvinblastineandprednisone AT daglimarialuciazaidan imatinibmesylateforthetreatmentofcaninemastcelltumorsassessmentoftheresponseandadverseeventsincomparisonwiththeconventionaltherapywithvinblastineandprednisone AT pintoanacarolinabcfonseca imatinibmesylateforthetreatmentofcaninemastcelltumorsassessmentoftheresponseandadverseeventsincomparisonwiththeconventionaltherapywithvinblastineandprednisone AT materajuliamaria imatinibmesylateforthetreatmentofcaninemastcelltumorsassessmentoftheresponseandadverseeventsincomparisonwiththeconventionaltherapywithvinblastineandprednisone |